Centyrin ligands for extrahepatic delivery of siRNA

RNA interference (RNAi) offers the potential to treat disease at the earliest onset by selectively turning off the expression of target genes, such as intracellular oncogenes that drive cancer growth. However, the development of RNAi therapeutics as anti-cancer drugs has been limited by both a lack...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther
Autors principals: Klein, Donna, Goldberg, Shalom, Theile, Christopher S., Dambra, Richard, Haskell, Kathleen, Kuhar, Elise, Lin, Tricia, Parmar, Rubina, Manoharan, Muthiah, Richter, Mark, Wu, Meizhen, Mendrola Zarazowski, Jeannine, Jadhav, Vasant, Maier, Martin A., Sepp-Lorenzino, Laura, O’Neil, Karyn, Dudkin, Vadim
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8178446/
https://ncbi.nlm.nih.gov/pubmed/33601052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2021.02.015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars